Profile data is unavailable for this security.
About the company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
- Revenue in USD (TTM)0.00
- Net income in USD-9.82m
- Incorporated2014
- Employees8.00
- LocationDermata Therapeutics Inc3525 Del Mar Heights Rd., #322SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 223-0882
- Fax+1 (302) 636-5454
- Websitehttps://www.dermatarx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiromic Biopharma Inc | 0.00 | -26.21m | 1.50m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Peak Bio Inc | 354.02k | -4.63m | 1.62m | -- | -- | -- | -- | 4.57 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -28.56m | 1.65m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
| Trevena Inc | 546.00k | -34.04m | 1.67m | 23.00 | -- | -- | -- | 3.05 | -47.76 | -47.76 | 0.7121 | -27.27 | 0.017 | -- | -- | 23,739.13 | -105.83 | -55.93 | -130.71 | -66.35 | -190.29 | -- | -6,233.70 | -3,134.41 | -- | -18.32 | 3.43 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| Hi-Great Group Holding Co | 69.41k | -54.82k | 1.78m | -- | -- | -- | -- | 25.64 | -0.0005 | -0.0005 | 0.0007 | -0.0014 | 0.7459 | 0.6517 | -- | -- | -58.91 | -- | -- | -- | 54.26 | -- | -78.98 | -- | 0.0276 | -15.03 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.85m | 6.00 | -- | 0.91 | -- | 34.21 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 1.92m | 51.00 | -- | -- | -- | 0.0960 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Pharmagreen Biotech Inc | 4.36k | -403.84k | 1.92m | 0.00 | -- | -- | -- | 441.42 | -0.0007 | -0.0007 | 0.00001 | -0.0034 | 0.0366 | 0.2274 | 7.33 | -- | -339.07 | -523.11 | -- | -- | 54.36 | -- | -9,263.30 | -307,598.30 | 0.0004 | -2.15 | -- | -- | -- | -- | 35.03 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 1.95m | 8.00 | -- | 0.2695 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -12.82m | 2.06m | 5.00 | -- | 0.086 | -- | -- | -2,217.58 | -2,217.58 | 0.00 | 16.98 | 0.00 | -- | -- | 0.00 | -52.54 | -- | -110.73 | -- | -- | -- | -- | -- | -- | -- | 0.0626 | -- | -- | -- | 3.02 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.09m | 2.00 | -- | 0.3914 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 2.18m | 62.00 | -- | 0.3068 | -- | 0.0857 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| Phio Pharmaceuticals Corp | 0.00 | -8.68m | 2.20m | 8.00 | -- | 0.3462 | -- | -- | -23.77 | -23.77 | 0.00 | 7.40 | 0.00 | -- | -- | 0.00 | -98.62 | -71.92 | -126.86 | -84.15 | -- | -- | -- | -253,785.70 | -- | -- | 0.00 | -- | -- | -- | 5.70 | -- | 0.00 | -- |
| Qrons Inc | 0.00 | -860.04k | 2.24m | 2.00 | -- | -- | -- | -- | -0.0632 | -0.0632 | 0.00 | -0.088 | 0.00 | -- | -- | 0.00 | -9,368.63 | -1,513.45 | -- | -- | -- | -- | -- | -- | -- | -9.21 | -- | -- | -- | -- | -7.61 | -- | -- | -- |
Data as of Nov 13 2024. Currency figures normalised to Dermata Therapeutics Inc's reporting currency: US Dollar USD
2.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 28.00k | 1.85% |
| Tower Research Capital LLCas of 30 Jun 2024 | 1.73k | 0.12% |
| UBS Securities LLCas of 30 Jun 2024 | 1.71k | 0.11% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.28k | 0.09% |
| Wells Fargo Clearing Services LLCas of 30 Jun 2024 | 45.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 3.00 | 0.00% |
| Citadel Securities LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
| The Northwestern Mutual Life Insurance Co. (Invt Port)as of 30 Jun 2024 | 0.00 | 0.00% |
| Geode Capital Management LLCas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
